Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 55Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Myelodysplastic Syndromes 42Leukemia, Lymphocytic, Chronic, B-Cell 40Leukemia 38Lymphoma, Non-Hodgkin 32Multiple Myeloma 31Lymphoma 31Lymphoma, Mantle-Cell 26Lymphoma, Follicular 24Lymphoma, Large B-Cell, Diffuse 23Hodgkin Disease 22Melanoma 21Burkitt Lymphoma 19Lymphoma, B-Cell, Marginal Zone 18Leukemia, Myelomonocytic, Chronic 17Recurrence 14Anemia, Refractory, with Excess of Blasts 14Congenital Abnormalities 13Neoplasms, Plasma Cell 12Myeloproliferative Disorders 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large-Cell, Immunoblastic 11Hematologic Neoplasms 11Leukemia, Myeloid, Chronic-Phase 10Primary Myelofibrosis 9Lymphoma, Large-Cell, Anaplastic 9Lymphoma, B-Cell 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Ovarian Neoplasms 8

Interventions

fludarabine 3itacitinib 2Alemtuzumab 2thymoglobulin 1ruxolitinib 1romidepsin 1niraparib 1nelarabine 1fludarabine phosphate 1duvelisib 1Stem Cell Transplantation 1Interleukin-15 1INCB039110 1GRN163L peptide 1Everolimus 1Depsipeptides 1Cytarabine 1Cyclophosphamide 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Prolymphocytic, T-Cell × fludarabine phosphate × Clear all
NCT02512497 2025-09-19

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
23 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡